Stage 4 Lung Cancer: 435 Real Stories

435 stories match lung cancer and stage 4. 243 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

EGFR-mutated stage IV lung cancer complicated by radiation lung injury and severe COVID-19

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR mutation; TP53 mutation

Metastatic Site: bone

Osimertinib produced a significant reduction in the lung lesions. She remained alive at the last follow-up in July 2023 after recovering from severe COVID-19 and treatment-related lung complications.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Lung cancer brain metastasis grew into a pre-existing meningioma

Patient Info: Anonymized, female, 70+ | Stage IV

Metastatic Site: brain

Six months after lung surgery, a pathologically confirmed brain metastasis developed beside and partly infiltrated a pre-existing meningioma. It was surgically removed, and the patient declined radiochemotherapy afterward.

PubMed Central
OutcomeSetback / Progression
Ivy, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV EGFR Lung Cancer: Ivy's Survivor Story

Patient Info: Ivy E., Female, 40s | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Bone: elbow, cervical spine/neck, rib, pelvis; brain

As of January 2024, Ivy reported no evidence of disease 1 year after right upper lobectomy, after years of response to EGFR-targeted therapy for initially Stage IV lung cancer.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV enteric-type lung adenocarcinoma with EGFR mutations and MSI-high disease

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M; MSI-high; high tumor mutation burden; MLH1 mutation; pMMR; PD-L1-negative

Metastatic Site: lung, pleura

The cancer progressed through multiple targeted, chemotherapy, and immunotherapy regimens. He died about 30 months after the initial diagnosis.

PubMed Central
OutcomeIn Memory
Deborah, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Deborah's Patient Story

Patient Info: Deborah Persinger, Female, 70+ | Stage IV

Metastatic Site: Brain

As of January 2024, Deborah was living actively 13 years after lung cancer diagnosis, with recurrent brain metastases managed through repeated Gamma Knife radiosurgery and ongoing MRI surveillance.

Cleveland Clinic
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Rare lung cancer first discovered as a mass in the skull

Patient Info: Anonymized, Male | Stage IV

Biomarkers: KRAS ; CK7-positive; CDX2-positive; pathology favoured pulmonary enteric adenocarcinoma

Metastatic Site: skull base / sphenoid sinus; right posterior acetabulum

He received palliative radiation and prolonged systemic therapy, completing 35 cycles including 31 maintenance cycles of pemetrexed and pembrolizumab.

PubMed Central
OutcomeNot reported
Tiffany, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Tiffany's Patient Story

Patient Info: Tiffany, Female, Under 40 | Stage IV

Metastatic Site: Pelvis; right femur; cervical spine

As of January 2024, Tiffany’s story described rapid diagnosis of Stage IV lung cancer and evaluation at MD Anderson, with treatment planning underway but specific treatment details not stated.

The Patient Story
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV EGFR-Mutant Lung Adenocarcinoma Responding to Osimertinib

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: EGFR L833V/H835L mutations; PD-L1 50%; CDK4 amplification; MDM2 amplification

Metastatic Site: contralateral lung, brain

After 3 months of osimertinib, the right upper lobe lesion had decreased and right hilar lymphadenopathy had resolved. The brain lesion remained stable, and subsequent imaging continued to show improvement in the lung lesion.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Lung cancer first discovered through a skin metastasis

Patient Info: Anonymized, Male | Stage IV

Metastatic Site: skin and subcutaneous tissues; soft tissue and muscle;…

His metastatic disease progressed rapidly, and he died 4.5 months after the initial dermatology referral.

PubMed Central
OutcomeIn Memory
Matt, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ALK Lung Cancer: Matt's Survivor Story

Patient Info: Matt Hiznay, Male, Under 40 | Stage IV

Biomarkers: ALK mutation / ALK-positive

Metastatic Site: Not reported

As of November 2023, Matt was a 12-year survivor with Stage IV ALK-positive lung cancer in remission, no evidence of disease, and ongoing lorlatinib treatment.

Cleveland Clinic
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Brain radiation therapy complication (radionecrosis) potentially linked to combined chemo-immunotherapy

Patient Info: Anonymized, Female | Stage IV

Biomarkers: PD-L1 0%; tumour mutational burden 33 mutations/Mb; TP53 mutation at diagnosis; later ctDNA included KEAP1 and NOTCH3 alterations

Metastatic Site: brain; presumed leptomeningeal disease

She recovered completely from surgery for radiation necrosis, resumed cancer treatment and remained neurologically intact at 18 months. She was found deceased 9 months later; the cause of death was unknown.

PubMed Central
OutcomeIn Memory
Christine, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ALK Non-Small Cell Lung Cancer: Christine's Patient Story

Patient Info: Christine, Female, 50s | Stage IV

Biomarkers: ALK mutation / ALK-positive

Metastatic Site: Brain | Liver

As of October 2023, Christine was living with Stage IV ALK-positive NSCLC that remained in check on targeted therapy after alectinib cleared brain and liver spots and lorlatinib continued, with significant chronic side effects.

Lung Cancer Research Foundation
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

BRCA2-Mutated Metastatic Lung Adenocarcinoma Controlled for 30 Months With Olaparib

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: PD-L1-negative; BRCA2 mutation; ATM mutation; EGFR-negative; ALK-negative

Metastatic Site: brain

Olaparib provided about 30 months of disease control, and PET imaging remained overall stable when a separate new breast primary was found in February 2023.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

MET-mutated lung cancer: testing savolitinib before surgery

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: MET exon 14 skipping, TP53 and BRAF mutations; PD-L1 expression 5%

Metastatic Site: pleura; mediastinal lymph node

Savolitinib produced a partial radiological response, but surgery confirmed persistent pleural and mediastinal nodal metastases with ypStage IVA disease. He recovered and continued adjuvant savolitinib.

PubMed Central
OutcomeIn Treatment
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Lung cancer recurrence in the thyroid, initially mistaken for thyroid cancer

Patient Info: Anonymized, Male | Stage IV

Biomarkers: EGFR exon 19 deletion; TTF-1-positive; Napsin A-positive; PAX8-negative; thyroglobulin staining limited to tumour cells adjacent to normal thyroid tissue

Metastatic Site: thyroid; cervical lymph nodes

After starting osimertinib for EGFR exon 19-deleted recurrent lung adenocarcinoma, he was disease free 5 months after thyroid surgery.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

HER2-positive metastatic lung cancer treated with trastuzumab deruxtecan (Enhertu)

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ERBB2/HER2 copy-number gain of at least 20 copies; TP53 C242fs; CDK12 copy-number gain; tumour mutational burden 3.2 mutations/Mb

Metastatic Site: lungs / multiple pulmonary nodules

Trastuzumab deruxtecan reduced the pulmonary nodules by more than 50% at 3 months and produced a documented response lasting 13.8 months.

PubMed Central
OutcomeResponding Well